Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
84.85 CHF | -0.18% | -1.49% | -0.02% |
Apr. 17 | Novartis' Multiple Sclerosis Drug Shows Sustained Efficacy for Up to Six Years | MT |
Apr. 17 | Novartis: positive efficacy data in MS | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.02% | 204B | |
+28.79% | 673B | |
+24.81% | 551B | |
-7.64% | 348B | |
+15.00% | 317B | |
+5.99% | 288B | |
+2.47% | 210B | |
-9.98% | 195B | |
-11.71% | 145B | |
-8.32% | 142B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis' Phase 3 Lung Cancer Drug Trial Fails to Meet Primary Endpoint; Shares Down Pre-Bell